Pharmacological research
Mitochondrial pyruvate dehydrogenase kinase 1 drives bevacizumab resistance and malignant phenotype of TNBC by enhancing mitophagy.
Yan Ye, Qian Zeng, Zuli Ou, Xiaoqian Ju, Qingyu Liao, Canling Li, Dian Zhang, Yu Wei, Xiang Zhang, Kejia Wu, Tingmei Chen
Published: 202510.1016/j.phrs.2025.108081
Abstract
Bevacizumab is an anti-angiogenic agent widely used in neoadjuvant chemotherapy for advanced triple-negative breast cancer (TNBC). TNBC patients frequently acquire resistance to bevacizumab due to the hypoxic tumor microenvironment, yet the underlyin…
Preview only. Read the full abstract at the source